All the IT systems of the European Medicines Agency (EMA) will be temporarily unavailable from 6 am U.K. time on Saturday, April 16 to 6 am Sunday the 17th (U.K. time) due to essential maintenance, according to an EMA announcement released yesterday.
All the IT systems of the European Medicines Agency (EMA) will be temporarily unavailable from 6 am U.K. time on Saturday, April 16 to 6 am Sunday the 17th (U.K. time) due to essential maintenance, according to an EMA announcement released yesterday.
“During these 24 hours, it will not be possible to access the EMA public website, or any other EMA-hosted website or online application, including the systems used to send and receive applications for EMA regulatory procedures. Normal service will resume on April 17,” the agency noted.
Emails sent to EMA email addresses during this period will be queued and delivered to recipients on the 17th. The EMA product emergency hotline and phone number for notifying suspected quality defects or product recalls will operate as usual. While the EMA public website is unavailable, a holding page will be displayed with details of these emergency numbers.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
2 Commerce Drive
Cranbury, NJ 08512